Mechanisms and changes of endogenous vasoconstrictive substances in development of diabetic nephropathy

Abstract

Abstract: Diabetic nephropathy (DN) is one of the most common microangiopathy complications in diabetes mellitus (DM). Many vasoactive substances are related to the development of DN. This article reviewed the mechanisms and changes of endogenous vasoconstrictive substances in the development of DN, also expected the possible treatment methods of DN.

Key words: angiotensin Ⅱ, endothelin-1, thromboxan A₂, urotensin Ⅱ, vasopressin, diabetic nephropathy, mechanism

CLC Number:

R587. 1

AN Na-qin, DING Xuan-sheng. Mechanisms and changes of endogenous vasoconstrictive substances in development of diabetic nephropathy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(5): 589-595.

References

[1] Nguyen G.Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro) renin receptor[J]. Kidney Int, 2006, 70(4): 618-620.
[2] Huang Y, Wongamorntham S, Kasting J, et al.Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms[J]. Kidney Int, 2006, 69 (1): 105-113.
[3] Persson F, Rossing P, Schjoedt KJ, et al.Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes[J]. Kidney Int, 2008, doi: 10.1038/ki.2008.68.
[4] Kagami S, Border WA, Miller DE, et al.Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells[J]. J Clin Invest, 1994, 93(6): 2431-2437.
[5] Papakonstantinou E, Roth M, Kokkas B.Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells[J]. J Cardiovasc Pharmacol, 2001, 38(5): 715-728.
[6] Nose A, Mori Y, Uchiy ama-TanaK_a Y, et al. Regulation of glucose transporter (GLUT1) gene expression by angiotensin ii in mesangial cells:involvement of HB-EGF and EGF receptor transactivation[J]. Hypertens Res, 2003, 26(1): 67-73.
[7] Yoshimoto T, Hirata Y.Aldosterone as a cardiovascular risk hormone[J]. Endocr J, 2007, 54(3): 359-370.
[8] Yuan J, Jia R, Bao Y.Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats[J]. J Renin Angiotensin Aldosterone Syst, 2007, 8 (3): 118-126.
[9] Han KH, Kang YS, Han SY, et al.Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats[J]. Kidney Int, 2006, 70(1): 111-120.
[10] Guo C, Martinez-Vasquez D, Mendez GP, et al.Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus[J]. Endocrinology, 2006, 147(11): 5363-5373.
[11] Van den Meiracker AH, Baggen RG, Pauli S, et al.Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function[J]. J Hypertens, 2006, 24(11): 2285-2292.
[12] Epstein M, Williams GH, Weinberger M, et al.Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes[J]. Clin J Am Soc Nephrol, 2006, 1(5): 940-951.
[13] Minchenko AG, StevensMJ, White L, et al.Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation [J]. FASEB J, 2003, 17 (11): 1514-1516.
[14] Ebihara I, Nakamura T, Tomino Y, et al.Effect of a specific endothelin receptor A antagonist and an angiotensinconverting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis[J]. Nephrol Dial Transplant, 1997, 12 (5): 1001-1006.
[15] Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an antiinflammatory mechanism[J]. J Am Soc Nephrol, 2007, 18 (1): 143-154.
[16] Pfab T, Thöne-Reineke C, Theilig F, et al.Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure[J]. J Am Soc Nephrol, 2006, 17(4): 1082-1089.
[17] Cosenzi A, Bernobich E, Trevisan R, et al. Nephroprotective effect of bosentan in diabetic rats[J]. J Cardiovasc Pharmacol, 2003, 42(6): 752-756.
[18] Hocher B, Schwarz A, Reinbacher D, et al.Effects of endothelin receptor antagonists on the progression of diabetic nephropathy[J]. Nephron, 2001, 87(2): 161-169.
[19] Hayama M, Akiba S, Fukuzumi M, et al.High glucoseinduced cytosolic phospholipase A2 activation responsible for eicosanoid production in rat mesangial cells[J]. J Biochem, 1997, 122(6): 1196-1201.
[20] Kiritoshi S, Nishikawa T, Sonoda K, et al.Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells:potential role in diabetic nephropathy[J]. Diabetes, 2003, 52(10): 2570-2577.
[21] Hishinuma T, Tsukamoto H, Suzuki K, et al. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications[J]. Prostaglandins Leukot Essent Fatty Acids, 2001, 65(4): 191-196.
[22] Makino H, Mukoyama M, Sugawara A, et al.Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment[J]. Clin Exp Nephrol, 2003, 7(1): 33- 40.
[23] Sebeková K, Eifert T, Klassen A, et al.Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes[J]. Diabetes, 2007, 56(4): 968-974.
[24] Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors[J]. Int Immunopharmacol, 2002, 2(13/14): 1771-1779.
[25] Simard B, Gabra BH, Sirois P.Inhibitory effect of a novel bradykinin B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice[J]. Can J Physiol Pharmacol, 2002, 80(12): 1203-1207.
[26] Allard J, Bulé on M, Cellier E, et al.ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats[J]. Am J Physiol Renal Physiol, 2007, 293(4): 1083-1092.
[27] Tan Y, Wang B, Keum JS, et al. Mechanisms through which bradykinin promotes glomerular injury in diabetes [J]. Am J Physiol Renal Physiol, 2005, 288(3): 483- 492.
[28] Tan Y, Keum JS, Wang B, et al.Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy[J]. Am J Physiol Renal Physiol, 2007, 293(4): 1026-1035.
[29] Langham RG, Kelly DJ, Gow RM, et al.Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy[J]. Am J Kidney Dis, 2004, 44(5): 826-831.
[30] Clozel M, Hess P, Qiu C, et al. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats[J]. J Pharmacol Exp Ther, 2006, 316 (3): 1115-1121.
[31] Sidharta PN, Wagner FD, Bohnemeier H, et al.Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients[J]. Clin Pharmacol Ther, 2006, 80(3): 246-256.
[32] Bardoux P, Martin H, Ahloulay M, et al.Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus:study in vasopressin-deficient Brattleboro rats[J]. Proc Natl Acad Sci USA, 1999, 96(18): 10397-10402.
[33] Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans:involvement of V2 receptors and the renin-angiotensin sy stem [J]. Nephrol Dial Transplant, 2003, 18(3): 497-506.
[34] Bardoux P, Bruneval P, Heudes D, et al.Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats[J]. Nephrol Dial Transplant, 2003, 18(9): 1755-1763.
[35] Gomez-Garre D, Ruiz-OrtegaM, Ortego M, et al.Effects and interactions of endothelin-1 and angiotensinⅡ on matrix protein expression and synthesis and mesangial cell growth[J]. Hypertension, 1996, 27(4): 885-892.